|
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Amplification or overexpression of neuronal MYC (MYCN) is associated with poor prognosis of human neuroblastoma.
|
26156430 |
2015 |
|
Neuroblastoma
|
0.600 |
PosttranslationalModification
|
disease |
BEFREE |
MYC has been shown to associate with DNA methyltransferases, thereby inducing transcriptional repression of target genes, which suggested that MYCN might play a similar mechanistic role in the hypermethylation of tumor suppressor genes in neuroblastoma.
|
23280764 |
2014 |
|
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Taken together our data suggest that these small molecules may hold potential as effective therapeutic agents for the treatment of neuroblastoma and other MYC-driven cancers.
|
24282277 |
2014 |
|
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
MYCN and MYC play a crucial role in determining the malignancy of unfavorable neuroblastomas, whereas high-level expression of the favorable neuroblastoma genes is associated with a good disease outcome and confers growth suppression of neuroblastoma cells.
|
24173829 |
2014 |
|
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
TFs like MYC and PTEN having six types of adjacent nodes and other classes of TFs investigated really can help to demonstrate that TFs affect pathways through expressions of significant miRNAs involved in the pathogenesis of NB.
|
25292042 |
2014 |
|
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In MYC-amplified neuroblastoma patient samples, there was a significant correlation between SHMT2 and hypoxia-inducible factor-1 α (HIF1α), and SHMT2 expression correlated with unfavorable patient prognosis.
|
25186948 |
2014 |
|
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The xenografts established from the NB iCSCs shared two common features: the LCN phenotype and high-level MYC/MYCN expression.
|
23479628 |
2013 |
|
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We found that MYCN/MYC-mediated overactivation of the metaphase-anaphase checkpoint synergizes with loss of p53-p21 function to prevent arrest or apoptosis of tetraploid neuroblastoma cells.
|
23186832 |
2013 |
|
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We review the latest approaches envisioned for blockade of ALK activity in neuroblastoma, present a classification of potential approaches for therapeutic targeting of MYCN, and discuss how recent developments in targeting of MYC proteins seem to make therapeutic inhibition of MYCN a reality in the clinic.
|
23965898 |
2013 |
|
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
For in vivo validation we selected CSNK1e, a kinase whose expression correlated with MYCN amplification in neuroblastoma (an established MYC-driven cancer).
|
22623531 |
2012 |
|
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
ATF4 regulates MYC-mediated neuroblastoma cell death upon glutamine deprivation.
|
23153536 |
2012 |
|
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
It was found that Hsp90 inhibition in neuroblastoma cell lines resulted in significant growth suppression, a decrease in MYCN and MYC expression, and an increase in the expression of p53.
|
21109931 |
2011 |
|
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The involvement of the MYC-MAX-MXD1 network in the development and progression of neural crest cell tumors is further supported by the lack of functional MAX in rat PCC (PC12) cells and by the amplification of MYCN in neuroblastoma and suggests that loss of MAX function is correlated with metastatic potential.
|
21685915 |
2011 |
|
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We further demonstrated that BMI1 is a direct target gene of MYCN/MYC in 3 neuroblastoma cell lines: BE (2)-C, LAN1, and SH-SY5Y.
|
21856782 |
2011 |
|
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We showed that Gas41 is able to bind both n-Myc and c-Myc proteins, and that the levels of expression of Gas41 and Myc proteins were similar to each other in such brain tumors as neuroblastomas and glioblastomas.
|
22068108 |
2011 |
|
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Using neuroblastoma as a tumor model, we established a microRNA (miRNA) signature for activated MYCN/c-MYC signaling in two independent primary neuroblastoma tumor cohorts and provide evidence that c-MYC and MYCN have overlapping functions.
|
19946337 |
2010 |
|
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
High-risk neuroblastomas (an often lethal embryonal tumor in which MYC activation is paramount) deregulate numerous polyamine enzymes to promote the expansion of intracellular polyamine pools.
|
19789308 |
2009 |
|
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Exposures mimicking conditions of CO (2) pneumoperitoneum lead to significant overexpression of C-MYC and HMGB-1 in neuroblastoma cells with decreased apoptosis.
|
19387923 |
2009 |
|
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We identified a genetic signature characterized by a subset of MYCN/MYC and E2F targets, including Skp2, encoding the F-box protein of the SCF(Skp2) E3-ligase, to be highly expressed in high-risk neuroblastomas independent of amplified MYCN.
|
17652624 |
2007 |
|
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Inhibition of c-myc and N-myc genes by dsRNAs in carcinoma and neuroblastoma cells was investigated. siRNA-Ex3 targeted to the third exon of c-myc gene was found to decrease the level of c-myc but not N-myc mRNA and decrease the rate or even arrest proliferation of c-myc overexpressing cell lines KB-3-1 and SK-N-MC.
|
17341633 |
2006 |
|
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Further, despite compelling evidence for MYC and RAS cooperation in vitro and in vivo to promote tumourigenesis, activation of RAS signal transduction does not constitute a preferred secondary pathway in neuroblastomas with MYCN deregulation in either human tumors or murine models.
|
16822308 |
2006 |
|
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our finding that MYCN directly modulates baseline MDM2 levels suggests a mechanism contributing to the pathogenesis of neuroblastoma and other MYC-driven malignancies through inhibition of MYC-stimulated apoptosis.
|
15644444 |
2005 |
|
Neuroblastoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Translocation (e.g., c-myc in Burkitt's lymphoma), or amplification (e.g., N-myc in neuroblastoma) of myc genes has been causally linked to tumor formation.
|
12769686 |
2003 |
|
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
As these results are of potential clinical importance, but not in agreement with our own initial observations, the putative correlation between ID2 and MYC(N) expression in neuroblastoma cell lines and tumors was reinvestigated.
|
12545167 |
2003 |
|
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
An element in the region responsible for premature termination of transcription mediates repression of c-myc gene expression by thyroid hormone in neuroblastoma cells.
|
10625678 |
2000 |